´╗┐

CCS News

Unprecedented times require unprecedented collaboration

Joint publication from 15 North American cardiovascular societies addresses how to safely reintroduce diagnostic and treatment services during the pandemic.

Read full press release.


Cardiac amyloidosis: evolving patient cares

The CCS/CHFS Joint Position Statement on the Evaluation and Management of Patients with Cardiac Amyloidosis joins a growing library of published guidelines and expert consensus statements aimed at facilitating delivery of optimal evidence-based patient care.
This statement provides detailed recommendations to assist cardiovascular health care providers along the spectrum of the patient journey, including clinical presentation and recognition of signs and symptoms, diagnostic investigations, management of cardiovascular manifestations (such as heart failure and arrhythmia), the use of novel disease-modifying therapies for ATTR and optimal care settings and considerations for follow-up and prognostic assessment.

Read the full publication in the Canadian Journal of Cardiology (CJC)


Better long-term outcomes for heart transplant recipients

Significant practice-changing developments have occurred in the care of heart transplantation candidates and recipients over the past decade. The CCS/CCTN Position Statement on Heart Transplantation: Patient Eligibility, Selection, and Post-Transplantation Care provides evidence-based, expert panel recommendations with values and preferences and practical tips on: (1) patient selection criteria; (2) selected patient populations; and (3) post transplantation surveillance.

The focus topics in this position statement highlight the increased complexity of patients who undergo evaluation for heart transplantation as well as improved patient selection and advances in post-transplantation management and surveillance that have led to better long-term outcomes for heart transplant recipients.

Read the full publication in the Canadian Journal of Cardiology (CJC)


POTS is a syndrome, not a specific disease

Postural orthostatic tachycardia syndrome (POTS) can be a challenging disorder to manage, both for providers and patients. An accurate and timely diagnosis, followed by a personalized management plan, can improve the quality of life for patients with POTS. The CCS Position Statement on POTS and Related Disorders of Chronic Orthostatic Intolerance provides recommendations to help guide health care providers in the diagnosis, evaluation and treatment of POTS.

Review how to recognize POTS and disorders of orthostatic intolerance that are not POTS, identify next steps in the diagnostic evaluation of POTS and examine the latest evidence regarding non-pharmacological and pharmacological management strategies for POTS in the full publication.

Read the full publication in the Canadian Journal of Cardiology (CJC)


COVID-19 and concerns regarding use of ACEi/ARB/ARNi medications for heart failure or hypertension

The Canadian Cardiovascular Society and the Canadian Heart Failure Society strongly discourage the discontinuation of guideline directed medical therapy (GDMT) involving Angiotensin Converting Enzyme Inhibitors (ACEi), Angiotensin Receptor Blockers (ARB) or Angiotensin Receptor Neprilysin Inhibitors (ARNi) in hypertensive or heart failure patients as a result of the COVID-19 pandemic.

Read more


The Canadian Cardiovascular Society announces new award for women in cardiovascular medicine and science

The Canadian Cardiovascular Society (CCS) is pleased to announce a new recognition award for women in cardiovascular medicine and science. The Women in Cardiovascular Medicine/Science Mentorship Award recognizes women who have demonstrated outstanding academic and/or clinical mentorship and appropriate guidance, feedback, and support to junior women in cardiovascular medicine/science.

Read full press release.


New clinical trial evidence for HF care

Using data from recent clinical trials, the 2019 Update of the CCS/CHSF HF Guidelines provides recommendations and practical tips regarding:

- transcatheter mitral valve repair in HFrEF,
- novel treatments for ATTR or transthyretin cardiac amyloidosis,
- ARNI in patients with HFpEF, and
- SGLT2 inhibitors for the prevention and treatment of HF in patients with or without type 2 diabetes.

Check out the full publication in the Canadian Journal of Cardiology (CJC).


New report shows access to and wait times for life-saving cardiac procedure depends on where you live, highlights need for new approaches to ensure pan-Canadian equity

In the last decade, transcatheter aortic valve implantation (TAVI) – an innovative, non-invasive surgical procedure – has become the preferred treatment option for many heart patients. Yet the latest pan-Canadian data on TAVI care shows that access is highly variable across Canada and that healthcare resources are not keeping pace with the growing healthcare need.

Read our full press release


The Canadian Cardiovascular Society announces recipients of the Early Career Atrial Fibrillation and Arrhythmia Award.

The Canadian Cardiovascular Society (CCS) is pleased to recognize seven outstanding Canadian researchers whose five projects have been selected to receive funding as part of the Early Career Atrial and Arrythmia (ECA3) Research Award.

Read our full press release


Finalists for the CCS-Bayer Vascular Award to be chosen during the Canadian Cardiovascular Congress

The Canadian Cardiovascular Society (CCS) has announced the three finalists in the CCS-Bayer Vascular Awards competition.

Read our full press release


Budget 2019 fails to include funding for the CCS Quality Project

Despite best efforts and major support at the highest level of government, federal Budget 2019 shows no sign of funds for the CCS Quality Project. Without this year’s federal funding commitment, the CCS will have no choice but to scale down the project, limiting our ability to advance quality cardiovascular care in Canada.

Read our full press release